Brian Macy, MD
Sports Medicine · Franklin, KYNPI 1154484277
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $383, 4.7 times the $82 reported in 2019.
Across 96 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$368
- Amgen$303
- Pfizer$138
- GSK$123
- Lilly USA, LLC$100
- Merck$97
- plus $469 from 17 others
What the payments were for
- Food & beverage$1,57899%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $368 |
| Amgen | 16 | $303 |
| Pfizer | 8 | $138 |
| GSK | 7 | $123 |
| Lilly USA, LLC | 6 | $100 |
| Merck | 7 | $97 |
| Bayer | 4 | $79 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Medtronic | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Pacira Therapeutics, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| Novartis | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
How this compares
$1,599 in reported general payments places this provider in the 65th percentile of 59 sports medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $141,859 |
| EliquisApixaban | 59 | $45,775 |
| JardianceEmpagliflozin | 31 | $31,868 |
| MounjaroTirzepatide | 28 | $30,827 |
| FarxigaDapagliflozin Propanediol | 34 | $25,965 |
| TrulicityDulaglutide | 14 | $24,237 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,311 |
| LinzessLinaclotide | 15 | $13,796 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $10,355 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $9,470 |
| Spiriva HandihalerTiotropium Bromide | 15 | $6,869 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,185 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $4,388 |
| Advair DiskusFluticasone Propion/Salmeterol | 15 | $2,948 |
| Atorvastatin Calcium | 368 | $2,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $14 | $141,859139 claims |
| Lilly USA, LLCMounjaro, Trulicity | $100 | $55,06442 claims |
| PfizerEliquis | $138 | $45,77559 claims |
| AstraZenecaFarxiga | $14 | $25,96534 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $123 | $21,49535 claims |
| AbbVieLinzess, Synthroid | $368 | $15,43456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 59 sports medicine providers in Kentucky.
Other sports medicine in Franklin
- Lindsey BrooksFranklin$2K
- Ryan KruppLouisville$803K
- Howard SchertzingerFlorence$147K
- Chaitanya MalempatiBowling Green$132K
- Scott MairLexington$59K
- Austin StoneLexington$15K
- Abigail DebuskBowling Green$15K
- Kyle ParishPaducah$10K
- Benjamin WilsonLexington$9K
- Nicholas Kenneyla Grange$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.